Mirogabalin
As of the edition of 20 October 2026, Mirogabalin is a small molecule: in active development; acts on CACNA2D1 and CACNA2D2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2014
- Kind
- Small molecule
- Registered trials
- 18, 0 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 2 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 9 | 9 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Lead sponsor of trials | 2011 to now |